These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12933558)

  • 21. Estimates of clinically useful measures in competing risks survival analysis.
    Ambrogi F; Biganzoli E; Boracchi P
    Stat Med; 2008 Dec; 27(30):6407-25. PubMed ID: 18937229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-dependent covariates in the proportional subdistribution hazards model for competing risks.
    Beyersmann J; Schumacher M
    Biostatistics; 2008 Oct; 9(4):765-76. PubMed ID: 18434297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart failure and sudden death in dilated cardiomyopathy: a hidden competition we should not forget about when modelling mortality.
    Gregori D; Rosato R; Zecchin M; Baldi I; Di Lenarda A
    J Eval Clin Pract; 2008 Feb; 14(1):53-8. PubMed ID: 18211644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A SAS macro for estimating transition probabilities in semiparametric models for recurrent events.
    Paes AT; de Lima AC
    Comput Methods Programs Biomed; 2004 Jul; 75(1):59-65. PubMed ID: 15158048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A missing data approach to semi-competing risks problems.
    Dignam JJ; Wieand K; Rathouz PJ
    Stat Med; 2007 Feb; 26(4):837-56. PubMed ID: 16755544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semiparametric regression in capture-recapture modeling.
    Gimenez O; Crainiceanu C; Barbraud C; Jenouvrier S; Morgan BJ
    Biometrics; 2006 Sep; 62(3):691-8. PubMed ID: 16984309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
    Crivellari D; Price K; Gelber RD; Castiglione-Gertsch M; Rudenstam CM; Lindtner J; Fey MF; Senn HJ; Coates AS; Collins J; Goldhirsch A;
    J Clin Oncol; 2003 Dec; 21(24):4517-23. PubMed ID: 14673038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semi-parametric inferences for association with semi-competing risks data.
    Ghosh D
    Stat Med; 2006 Jun; 25(12):2059-70. PubMed ID: 16196081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A non-parametric procedure for evaluating treatment effect in the meta-analysis of survival data.
    Moodie PF; Nelson NA; Koch GG
    Stat Med; 2004 Apr; 23(7):1075-93. PubMed ID: 15057879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analyses of cumulative incidence functions via non-parametric multiple imputation.
    Ruan PK; Gray RJ
    Stat Med; 2008 Nov; 27(27):5709-24. PubMed ID: 18712779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian adjustment for covariate measurement errors: a flexible parametric approach.
    Hossain S; Gustafson P
    Stat Med; 2009 May; 28(11):1580-600. PubMed ID: 19226564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A resampling approach for adjustment in prediction models for covariate measurement error.
    Li W; Mazumdar S; Arena VC; Sussman N
    Comput Methods Programs Biomed; 2005 Mar; 77(3):199-207. PubMed ID: 15721649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semiparametric analysis of mixture regression models with competing risks data.
    Lu W; Peng L
    Lifetime Data Anal; 2008 Sep; 14(3):231-52. PubMed ID: 18193354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of tamoxifen in pT1a-pT1b, pN0 breast cancer.
    Livi L; Saieva C; Paiar F; Simontacchi G; Galardi A; De Luca Cardillo C; Mangoni M; Paoletti L; Ponticelli P; Biti GP
    Eur J Surg Oncol; 2007 Apr; 33(3):271-5. PubMed ID: 16831531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data.
    Pullenayegum EM; Willan AR
    Stat Med; 2007 Jul; 26(17):3274-99. PubMed ID: 17309112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
    Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
    Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer.
    Fennessy M; Bates T; MacRae K; Riley D; Houghton J; Baum M
    Br J Surg; 2004 Jun; 91(6):699-704. PubMed ID: 15164437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.